Note 6 - Revenues

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

(

6

) REVENUES:

The Company operates in

one

business segment, which primarily focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The Company considers there to be revenue concentration risks for regions where net product revenues exceed

10%

of consolidated net product revenues. The concentration of the Company’s net product revenues within the regions below

may

have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties. The Company adopted the requirements of ASC

606

on

January 1, 2018

using the modified retrospective method. See Note

1

(h) – Revenue Recognition for additional discussion.

Revenues by product are summarized as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Trappsol Cyclo	$	73,500	$	-	$	103,596	$	166,596
Trappsol HPB		152,784		125,944		359,530		305,706
Trappsol research		57,620		57,798		162,572		175,200
Aquaplex		-		37,486		149,690		116,081
Other		2,010		3,252		4,447		8,381
Total revenues	$	285,914	$	224,480	$	779,835	$	771,964

Substantially all of our sales of Trappsol® Cyclo™ for the

nine

months ended

September 30, 2019

and

September 30, 2018

were to a particular customer who exports the drug to South America. Substantially all of our Aquaplex sales are also to

one

customer.